110 related articles for article (PubMed ID: 1899039)
1. Combination effect of recombinant human interleukin 1 alpha with antitumor drugs on syngeneic tumors in mice.
Nakamura S; Kashimoto S; Kajikawa F; Nakata K
Cancer Res; 1991 Jan; 51(1):215-21. PubMed ID: 1899039
[TBL] [Abstract][Full Text] [Related]
2. Antitumor effect of recombinant human interleukin 1 alpha against murine syngeneic tumors.
Nakamura S; Nakata K; Kashimoto S; Yoshida H; Yamada M
Jpn J Cancer Res; 1986 Aug; 77(8):767-73. PubMed ID: 3093425
[TBL] [Abstract][Full Text] [Related]
3. [Combined effect of PT-050 (recombinant human TNF) and antitumor drugs on syngeneic murine tumors].
Nakata K; Yoshida H; Kashimoto S; Sohmura Y; Nakamura S; Taguchi T
Gan To Kagaku Ryoho; 1986 Oct; 13(11):3186-93. PubMed ID: 3096217
[TBL] [Abstract][Full Text] [Related]
4. Augmented antitumor effect of recombinant human interleukin-1 alpha by indomethacin.
Nakata K; Kashimoto S; Yoshida H; Oku T; Nakamura S
Cancer Res; 1988 Feb; 48(3):584-8. PubMed ID: 3257168
[TBL] [Abstract][Full Text] [Related]
5. [Potentiation of chemotherapeutic activity by a Chinese herb medicine juzen-taiho-toh].
Komiyama K; Hirokawa Y; Zhibo Y; Umezawa I; Hata T
Gan To Kagaku Ryoho; 1988 May; 15(5):1715-9. PubMed ID: 3130806
[TBL] [Abstract][Full Text] [Related]
6. Augmentation of antitumor efficacy by the combination of recombinant tumor necrosis factor and chemotherapeutic agents in vivo.
Krosnick JA; Mulé JJ; McIntosh JK; Rosenberg SA
Cancer Res; 1989 Jul; 49(14):3729-33. PubMed ID: 2736513
[TBL] [Abstract][Full Text] [Related]
7. Recombinant human tumor necrosis factor-alpha: evidence of an indirect mode of antitumor activity.
Manda T; Shimomura K; Mukumoto S; Kobayashi K; Mizota T; Hirai O; Matsumoto S; Oku T; Nishigaki F; Mori J
Cancer Res; 1987 Jul; 47(14):3707-11. PubMed ID: 3594435
[TBL] [Abstract][Full Text] [Related]
8. Schedule-dependent variations in the response of murine P388 leukemia to cyclophosphamide in combination with interferons-alpha/beta.
Borden EC; Sidky YA; Hatcher JF; Bryan GT
Cancer Res; 1988 May; 48(9):2329-34. PubMed ID: 3356000
[TBL] [Abstract][Full Text] [Related]
9. In vivo antitumor activity of multiple injections of recombinant interleukin 2, alone and in combination with three different types of recombinant interferon, on various syngeneic murine tumors.
Iigo M; Sakurai M; Tamura T; Saijo N; Hoshi A
Cancer Res; 1988 Jan; 48(2):260-4. PubMed ID: 2446744
[TBL] [Abstract][Full Text] [Related]
10. Chemotherapy with [SP-4-3-(R)]-[1,1-cyclobutanedicarboxylato(2-)](2- methyl-1,4-butanediamine-N,N')platinum (CI-973, NK121) in combination with standard agents against murine tumors in vivo.
Elliott WL; Roberts BJ; Howard CT; Leopold WR
Cancer Res; 1994 Aug; 54(16):4412-8. PubMed ID: 8044790
[TBL] [Abstract][Full Text] [Related]
11. Potentiation of mitomycin C and porfiromycin antitumor activity in solid tumor models by recombinant human interleukin 1 alpha.
Braunschweiger PG; Jones SA; Johnson CS; Furmanski P
Cancer Res; 1991 Oct; 51(20):5454-60. PubMed ID: 1913664
[TBL] [Abstract][Full Text] [Related]
12. Antitumor activity and biochemical effects of aphidicolin glycinate (NSC 303812) alone and in combination with cisplatin in vivo.
O'Dwyer PJ; Moyer JD; Suffness M; Harrison SD; Cysyk R; Hamilton TC; Plowman J
Cancer Res; 1994 Feb; 54(3):724-9. PubMed ID: 8306334
[TBL] [Abstract][Full Text] [Related]
13. [Prolongation of survival and antitumor activity of antitumor drugs in murine cancer cachexia model].
Nukatsuka M; Fujioka A; Saito H; Uchida J; Takeda S; Unemi N
Gan To Kagaku Ryoho; 1996 Jun; 23(7):887-92. PubMed ID: 8678537
[TBL] [Abstract][Full Text] [Related]
14. Chemoprotective effects of recombinant human IL-1 alpha in cyclophosphamide-treated normal and tumor-bearing mice. Protection from acute toxicity, hematologic effects, development of late mortality, and enhanced therapeutic efficacy.
Futami H; Jansen R; MacPhee MJ; Keller J; McCormick K; Longo DL; Oppenheim JJ; Ruscetti FW; Wiltrout RH
J Immunol; 1990 Dec; 145(12):4121-30. PubMed ID: 2258610
[TBL] [Abstract][Full Text] [Related]
15. Optimal scheduling of interleukin 12 and chemotherapy in the murine MB-49 bladder carcinoma and B16 melanoma.
Teicher BA; Ara G; Buxton D; Leonard J; Schaub RG
Clin Cancer Res; 1997 Sep; 3(9):1661-7. PubMed ID: 9815857
[TBL] [Abstract][Full Text] [Related]
16. Antitumor efficacy of interleukin-2 alone and in combination with adriamycin and dacarbazine in murine solid tumor systems.
LoRusso PM; Aukerman SL; Polin L; Redman BG; Valdivieso M; Biernat L; Corbett TH
Cancer Res; 1990 Sep; 50(18):5876-82. PubMed ID: 2393858
[TBL] [Abstract][Full Text] [Related]
17. Combination cytokine immunotherapy with tumor necrosis factor alpha, interleukin 2, and alpha-interferon and its synergistic antitumor effects in mice.
McIntosh JK; Mulé JJ; Krosnick JA; Rosenberg SA
Cancer Res; 1989 Mar; 49(6):1408-14. PubMed ID: 2784349
[TBL] [Abstract][Full Text] [Related]
18. Acute in vivo resistance in high-dose therapy.
Teicher BA; Ara G; Keyes SR; Herbst RS; Frei E
Clin Cancer Res; 1998 Feb; 4(2):483-91. PubMed ID: 9516940
[TBL] [Abstract][Full Text] [Related]
19. [Combination therapy of a new platinum complex, DWA2114R with various antitumor agents against mouse tumors in vivo].
Akamatsu K; Endo K; Tsunenari T; Matsumoto T; Kaiho S; Morikawa K; Koizumi M; Mitsui H; Koizumi K
Gan To Kagaku Ryoho; 1992 Feb; 19(2):229-35. PubMed ID: 1736835
[TBL] [Abstract][Full Text] [Related]
20. Synergistic antitumor activity of cisplatin and interleukin 1 in sensitive and resistant solid tumors.
Braunschweiger PG; Basrur VS; Santos O; Markoe AM; Houdek PV; Schwade JG
Cancer Res; 1993 Mar; 53(5):1091-7. PubMed ID: 8439953
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]